- Market value & growth: This is a market valued at $2.0 billion in 2020 that is forecast to grow 4.0% per year to $2.45 billion by 2025. The pandemic did result in a shift to more telehealth services. Treatment programs generate $1.4 billion, while the medications market is worth $627 million.
- Key forecasts: Treatment center revenues are expected to grow 4.5% per year from 2021 to 2025, outpacing the growth of the autism drugs market, which is forecast to grow 3.0% per year (average annual rate).
- The need for treatment: The number of autistic children is rising in the United States, at the rate of 6.2% per year. The CDC now estimates that 1 in 54 children born in the U.S. are autistic.
- More treatment centers: The overwhelming majority of the largest for-profit treatment companies has increased the number of centers they operate, and their revenues, compared to 2017.
- The autism drugs market: Several medications (Risperdal, Concerta) are still used to treat people with autism, and less costly generics have entered the market, resulting in lower total revenues. There is substantial R&D taking place to develop new and more effective drugs.
- Health insurance coverage for autism: Insurance coverage of autistic children has improved over the past four years, with 64% now covered (vs. 36% in 2016). All 50 states now cover it.
- Revenue estimates: The top 9 for-profit chains are estimated to have posted 2019 revenues of $547 million.
About the Author: John LaRosa is the President of Marketdata LLC and is the author of 100+ industry and market studies. His research appears in top media outlets including ABC, CNN, Fox, Forbes, USA Today, The Wall Street Journal, The New York Times, and a variety of trade journals.